NervGen Pharma share price logo

NervGen Pharma

NASDAQ: NGEN

$1.59

-0.03

(-1.85%)

as on

NervGen Pharma Stock Performance

as on October 17, 2026 at 2:15 pm IST

  • Day's Low

    Day's High

    $1.58
    $1.66
    downward going graph

    0.63%

    Downside

    4.40%

    Upside

    downward going graph
  • 52 Week's Low

    52 Week's High

    downward going graph

    100.00%

    Downside

    -100.00%

    Upside

    downward going graph

NervGen Pharma share price movements today

Previous Close
$1.62
Open
$1.63
Volume
385.4K
Market Cap
$174.2M
Day's Low - High
$1.58 - $1.66

NervGen Pharma Historical Returns

1 Month Return
-29.96 %
3 Month Return
-4.79 %
1 Year Return
0 %
3 Year Return
0 %
5 Year Return
0 %

NervGen Pharma Stock Fundamentals & Key Indicators

Check NervGen Pharma market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$174.2M

EPS (TTM)

-0.8457

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

-2.71

Industry PE ratio

-3.02

PEG Ratio

0.03

EBITDA

-11.6M

Revenue (TTM)

-

Profit Margin

0.00%

Return On Equity TTM

-1156.14%

NervGen Pharma vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of NervGen Pharma with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
Buy$174.2MNA-2.710.00%0.00%
Neutral$94.4B-32.76%-29.64-12.57%0.00%
StrongBuy$128.9B174.93%29.3786.04%0.00%
Buy$80.1B42.93%19.0184.86%0.46%

Analyst Recommendation on NervGen Pharma Stock

Based on 2 analysts

BUY

100.00%

Buy

0.00%

Hold

0.00%

Sell

Based on 2 analysts, 100% of analysts recommend a 'BUY' rating for NervGen Pharma. Average target price of $10

NervGen Pharma Share Price Target

Get share price movements and forecasts by analysts on NervGen Pharma.

Current Price

$1.59

Analyzed by

2 Analysts

High

$10

0

Low

$10

NervGen Pharma target price $0, a slight upside of 0% compared to current price of $1.59. According to 2 analysts rating.

Indian Investors' Interest in NervGen Pharma Stock

Search interest for NervGen Pharma Stock has decreased by -13% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-13% versus previous 30 day period

NervGen Pharma Quarterly Profit & Loss

All numbers in Millions USD

Jun 2023
Sep 2023
Mar 2024
Jun 2024
Sep 2024
Mar 2025
Jun 2025
Sep 2025
Mar 2026
Jun 2026
Total Revenue
-
-
-
-
-
-
-
-
-
-
Gross Profit
0
0
0
0
0
0
0
0
0
0
Operating Income
-4
-3
-4
-
-7
-6
-6
-6
-7
-12
EBITDA
-4
-4
-2
-7
-5
-3
-9
-4
-1
-12
Interest Expense
-
-
-
-
-
-
-
-
-
-
Depreciation
0
0
0
0
0
0
0
0
0
0
Income Before Tax
-4
-4
-2
-7
-5
-3
-9
-4
-1
-29
Income Tax Expense
-
-
-
-
-
-
-
-
-
-
Net Income
-4
-4
-2
-7
-5
-3
-9
-4
-1
-29
Net Profit Margin
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%

NervGen Pharma Annual Profit & Loss

All numbers in Millions USD

Dec 2017
Mar 2020
Mar 2021
Dec 2021
Dec 2022
Mar 2024
Mar 2025
Mar 2026
Total Revenue
-
-
-
-
-
-
-
-
Gross Profit
-
0
0
0
0
0
0
-
Operating Income
0
-10
-11
-12
-22
-17
-24
-25
EBITDA
0
-9
-11
-12
-19
-22
-23
-5
Interest Expense
-
-
-
-
0
-
-
-
Depreciation
0
0
0
0
0
0
0
0
Income Before Tax
0
-10
-11
-12
-20
-22
-23
-44
Income Tax Expense
-
-
-
-
-
-
-
-
Net Income
0
-10
-11
-12
-20
-22
-23
-44
Net Profit Margin
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%

NervGen Pharma Quarterly Cash Flow

All numbers in Millions USD

Jun 2023
Sep 2023
Mar 2024
Jun 2024
Sep 2024
Mar 2025
Jun 2025
Sep 2025
Mar 2026
Jun 2026
Net Income
-4
-4
-2
-7
-5
-3
-9
-4
-1
-29
Operating Cash Flow
-1
-1
-3
-4
-5
-4
-3
-5
-8
-5
Investing Cash Flow
0
0
-
0
0
0
0
0
0
0
Financing Cash Flow
0
0
22
0
0
1
4
0
2
80
Change in Cash
-1
-1
18
-4
-5
-2
1
-4
-5
70

NervGen Pharma Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Mar 2020
Mar 2021
Dec 2021
Dec 2022
Mar 2024
Mar 2025
Mar 2026
Net Income
0
-1
-10
-11
-12
-20
-22
-23
-44
Operating Cash Flow
-
-1
-8
-6
-8
-17
-11
-16
-19
Investing Cash Flow
-
0
-
0
0
0
0
0
0
Financing Cash Flow
-
3
10
7
19
22
0
22
23
Change in Cash
-
2
1
1
11
4
-10
4
4

Global Institutional Holdings in NervGen Pharma

Check out the Institutions with significant holdings in NervGen Pharma.

Funds
Holdings
Michael Rockefeller
0.23%
State Street
0.06%
iShares
0.01%

NervGen Pharma News & Key Events

  • img

    Today's Timeline - 25 September

    Fri, 10:01 PM

    -

    NervGen Pharma updates on RESTORE trial for NVG-291, aiming to improve function in chronic spinal cord injury patients.

    Sat, 02:10 AM

    -

    NervGen to restate financial statements for 2024-2026 due to non-cash accounting errors, impacting stock-based compensation and warrant liabilities.

    Sat, 02:29 AM

    -

    NervGen's audit committee advises against reliance on past financial statements due to discovered non-cash valuation errors.

Insights on NervGen Pharma

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgNEGATIVE IMPACT

    Price Dip

    img

    In the last 6 months, NGEN stock has moved down by -60.9%

About NervGen Pharma

NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer's disease; and NVG-300, which is in a preclinical model of ischemic stroke, amyotrophic lateral sclerosis, and confirmatory SCI study. NervGen Pharma Corp. has a licensing agreement with Case Western Reserve University to develop and commercialize a patented technology with therapeutic potential for spinal cord injury and other conditions associated with nerve damage. NervGen Pharma Corp. was incorporated in 2017 and is headquartered in Vancouver, Canada.
OrganisationNervGen Pharma
Headquarters112-970 Burrard Street, West Vancouver, BC, V6Z 2R4, CA
IndustryBiotechnology
CEOAdam H. Rogers

Key Management of NervGen Pharma

Name

Title

Ms. Shamim Ruff M.S.

Chief Regulatory Affairs Officer

Ms. Christine McSherry

Senior Vice President of Patient Advocacy & Clinical Affairs

Ms. Marissa Volpe

SVP of Clinical Development

Dr. Adam H. Rogers M.D.

President, CEO & Chairman

Dr. Harold Martin Punnett D.M.D.

Co-Founder & Independent Director

Dr. Randall E. Kaye M.D.

Chief Medical Advisor & Director

Dr. Keith A. Vendola M.B.A., M.D.

Chief Financial Officer

Dr. Charles V. Olson D.Sc.

Senior Vice President of Technical Operations

FAQs

What is NervGen Pharma share price today?

NervGen Pharma share price today is $1.59 as on at the close of the market. NervGen Pharma share today touched a day high of $1.66 and a low of $1.58.

What is the 52 week high and 52 week low for NervGen Pharma share?

NervGen Pharma share touched a 52 week high of $0.00 on and a 52 week low of $0.00 on . NervGen Pharma stock price today i.e. is closed at $1.59,which is -Infinity% down from its 52 week high and Infinity% up from its 52 week low.

What is NervGen Pharma's market capitalisation today?

NervGen Pharma market capitalisation is $0.00T as on .

How to invest in NervGen Pharma Stock (NGEN) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for NervGen Pharma on INDmoney app. Click on Buy button.

What is the minimum amount required to buy NervGen Pharma Stock (NGEN) from India?

Indian investors can start investing in NervGen Pharma (NGEN) shares with as little as ₹94.959999084473 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹949.60 in NervGen Pharma stock (as per the Rupee-Dollar exchange rate as on ). Based on NervGen Pharma share’s latest price of $1.59 as on October 17, 2026 at 8:45 am IST, you will get 6.2893 shares of NervGen Pharma. Learn more about fractional shares .